Targeted first-line treatment for advanced kidney cancer based on protein profile
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a first-line precision treatment for clear cell kidney cancer that has spread or cannot be removed. It aims to match the treatment to your cancer's protein profile to improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have advanced clear cell kidney cancer that has not been treated before
- You have at least one tumor that can be measured on scans
- You are in generally good health (ECOG score 0 or 1)
- Your blood and organ function tests are within acceptable limits
- You are willing to provide a tissue sample from your tumor
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new drug combination for people with advanced kidney cancer. The main drug, BL-B01D1, is given together with a targeted therapy (TKI) and sometimes also with an immunotherapy drug (pembrolizumab). The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests a new drug (JS004) combined with an existing immunotherapy (toripalimab) for kidney cancer that has progressed after previous immunotherapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This study looks at genetic (RNA) testing of kidney cancer tissue to help choose the best drug treatment. It may help guide therapy for people with advanced or metastatic clear cell kidney cancer who are starting treatment for the first time.
This trial tests a combination of two drugs — an immunotherapy (toripalimab) and a targeted therapy (axitinib) — as the first treatment for advanced kidney cancer. The approach may shrink the tumor before deciding whether and when to remove the kidney surgically.
This trial tests a combination of two drugs (SLC-3010 and axitinib) versus axitinib alone for people with advanced clear cell kidney cancer that has progressed after initial treatment. It aims to see if the combination is safer and more effective.
This trial tests a combination of two drugs, cardenilimab and lenvatinib, given before and after surgery to remove kidney cancer. The goal is to see if this approach helps prevent the cancer from coming back. It is for people with early-stage (non-spread) clear cell kidney cancer who are healthy enough for surgery.
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.